Content
Search
Navigation
Sitemap
About us
Pipeline & science
Overview
Hypertrophic cardiomyopathy (HCM)
Heart failure (HF)
Paroxysmal supraventricular tachycardia (PSVT)
Atrial fibrillation (AFib)
Dry eye disease (DED)
Presbyopia
Our expertise
Overview
Our partners
China opportunities
Join us
Media
Contact
简体中文
Search
简体中文
Navigation
Media
29 Jun 2022
JIXING Announces Receipt of Clinical Trial Application Approval for China Cohort of Phase 3 Clinical Trial of Aficamten
Read article
09 May 2022
Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program
Read article
20 Apr 2022
JIXING Announces Leadership Transition
Read article
14 Apr 2022
LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics
Read article
31 Mar 2022
JIXING Announces the Appointment of Kun Wu as the Chief Commercial Officer
Read article
21 Mar 2022
JIXING Announces Receipt of Clinical Trial Application Approval for OC-01 Nasal Spray Phase 3 Trial for the Treatment of Signs and Symptoms of Dry Eye Diseases in China
Read article
Load more